Mitochondria-Derived Peptide

MOTS-c Research Guide: Mitochondrial Peptide & AMPK Activation (2025)

Published 2025-04-04 · 13 min read · For Research Use Only

MOTS-c is a 16-residue peptide encoded within the mitochondrial 12S rRNA gene — making it one of the few peptides with a mitochondrial (non-nuclear) genetic origin. Discovered in 2015 by Lee et al., it has since been characterised as a potent metabolic regulator that mimics key aspects of exercise-induced AMPK signalling, improving insulin sensitivity, mitochondrial efficiency, and metabolic flexibility.

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide (MRWQEMGYIFYPRKLR) encoded within the 12S ribosomal RNA gene of the mitochondrial genome. It belongs to a growing family of mitochondria-derived peptides (MDPs) that includes humanin and SHLP1-6.

Its discovery in 2015 (Lee, Bhanu, et al., Cell Metabolism) represented a paradigm shift — demonstrating that mitochondria encode functional peptides with systemic hormonal-like signalling capacity. MOTS-c can be secreted from cells and act in an autocrine, paracrine, and endocrine fashion, accumulating in skeletal muscle, liver, and blood in response to metabolic stress.

SequenceMRWQEMGYIFYPRKLR (16 AA)
Genomic SourceMitochondrial 12S rRNA ORF
MW~2,172 Da
Primary TargetAMPK activation (via AICAR/folate cycle)
Discovered2015 — Lee et al., Cell Metabolism
Expression↑ by exercise, cold, caloric restriction; ↓ in aging/obesity

Mitochondrial Origin — Why It Matters

Mitochondria are evolutionarily derived from an ancient proteobacterial endosymbiont. Their genome (mtDNA, 16,569 bp in humans) is typically described as encoding only 13 proteins (respiratory chain subunits) plus rRNA and tRNA genes. MOTS-c demonstrates that this annotation was incomplete — small ORFs within rRNA genes can encode biologically active peptides.

The mitochondrial encoding has important implications:

  • Metabolic coupling: Mitochondrial gene expression is directly regulated by the mitochondria's own oxidative state — meaning MOTS-c production increases when mitochondria are metabolically stressed, creating an intrinsic feedback loop
  • Nuclear-mitochondrial communication: MOTS-c translocates to the nucleus during stress and modulates nuclear gene expression, establishing a retrograde signalling pathway from mitochondria to nucleus
  • Evolutionary conservation: MOTS-c has partial sequence conservation across species, suggesting evolutionary importance in metabolic regulation

AMPK Activation Mechanism

MOTS-c's primary mechanism involves the folate cycle and one-carbon metabolism pathway, leading to AMPK activation:

🔬
Folate Cycle Inhibition

MOTS-c inhibits key folate cycle enzymes → accumulation of AICAR (AICA ribonucleotide)

AMPK Activation

AICAR directly activates AMPK → ↑ fatty acid oxidation, ↑ glucose uptake, ↓ mTOR/lipogenesis

🏃
Exercise Mimicry

AMPK activation pattern mirrors exercise response — ↑ GLUT4 translocation, ↑ mitochondrial biogenesis

🧬
Nuclear Signalling

Under stress, MOTS-c translocates to nucleus → modulates ARE-driven gene expression

The AICAR pathway is particularly significant because AICAR is also the mechanism by which metformin and physical exercise activate AMPK — placing MOTS-c in mechanistic context with established metabolic interventions.

Metabolic Effects in Preclinical Research

Insulin Sensitivity

In multiple rodent models, MOTS-c administration significantly improves insulin sensitivity. In high-fat diet (HFD)-induced insulin resistance:

  • MOTS-c (5 mg/kg IP daily × 4 weeks) normalised fasting glucose, insulin, and HOMA-IR in HFD mice
  • Improved glucose clearance in GTT (glucose tolerance test) comparably to exercise training
  • Increased GLUT4 expression and membrane translocation in skeletal muscle

Adiposity & Lipid Metabolism

  • Reduced visceral fat accumulation in HFD models without reducing food intake
  • Increased fatty acid oxidation in skeletal muscle (↑ CPT1 expression)
  • Improved hepatic lipid metabolism with reduced hepatic triglyceride accumulation

Mitochondrial Function

  • Enhanced mitochondrial biogenesis (↑ PGC-1α, TFAM expression)
  • Improved mitochondrial coupling efficiency (higher ATP/O ratio)
  • Reduced mitochondrial ROS production in metabolically stressed cells

Exercise Mimicry Research

One of the most striking findings in MOTS-c research is its ability to partially replicate the molecular signature of endurance exercise:

Exercise vs MOTS-c: Shared Molecular Targets

PathwayEndurance ExerciseMOTS-c (5 mg/kg)
AMPK activation✓ (strong)✓ (strong)
GLUT4 translocation
PGC-1α upregulation
Mitochondrial biogenesis
Fatty acid oxidation ↑
Physical performance✓ (improved run time in aged mice)

A 2021 paper (Reynolds et al., Nature Communications) demonstrated that MOTS-c injections in aged mice (18 months) improved physical performance, increased muscle mass preservation, and reduced metabolic dysfunction — effects comparable to those seen with exercise training programs in the same model.

Longevity & Aging Research

MOTS-c levels decline with age in humans and rodents, mirroring the metabolic deterioration of aging. This decline correlates with reduced insulin sensitivity, increased adiposity, and decreased mitochondrial efficiency — all hallmarks of metabolic aging.

Key longevity-related findings:

  • Human epidemiology: A specific MOTS-c variant (K14Q) is enriched in Japanese centenarians and associated with reduced age-related metabolic decline (Lee et al., 2015)
  • Aged rodent restoration: MOTS-c supplementation in 18-month-old mice restores metabolic parameters closer to 3-month-old values, including insulin sensitivity, body composition, and mitochondrial function
  • Cellular senescence: MOTS-c reduces markers of cellular senescence (p21, p16) in metabolically stressed cells in vitro
MOTS-c research is in early stages. All reported effects are from preclinical (animal) models or in vitro studies. Human clinical trial data is limited as of 2025.

Research Protocols

Insulin Sensitivity (HFD Model)

  • Model: C57BL/6 mice, 16-week HFD
  • Dose: 5 mg/kg IP or SC daily
  • Duration: 4–8 weeks
  • Endpoints: GTT, ITT, HOMA-IR, fasting glucose/insulin

Exercise Performance (Aged Model)

  • Model: 18-month-old C57BL/6 mice
  • Dose: 5–15 mg/kg SC × 21 days
  • Endpoints: Treadmill run-to-exhaustion, grip strength, VO₂max
  • Compare: Vehicle, exercise training, MOTS-c + exercise

Mitochondrial Function (In Vitro)

  • Cell type: C2C12 myotubes, primary hepatocytes
  • Treatment: 1–10 µM MOTS-c × 24–72h
  • Endpoints: Seahorse XF (OCR/ECAR), AMPK phosphorylation (Western)
  • Controls: AICAR positive control, Compound C (AMPK inhibitor)

FAQ

What is MOTS-c?

A 16-amino acid peptide encoded in the mitochondrial genome's 12S rRNA gene. It activates AMPK via the folate cycle/AICAR pathway, mimicking key aspects of exercise-induced metabolic signalling.

How does MOTS-c activate AMPK?

MOTS-c inhibits folate cycle enzymes, causing accumulation of AICAR — which directly activates AMPK. This is the same upstream mechanism as metformin and exercise-induced AMPK activation.

Is MOTS-c naturally occurring?

Yes — it is encoded in the mitochondrial genome and naturally produced by cells. Its circulating levels increase with exercise, cold exposure, and caloric restriction, and decline with aging and obesity.

What distinguishes MOTS-c from other exercise mimetics?

MOTS-c has a mitochondrial genetic origin — unlike most exercise mimetics (e.g., GW501516, AICAR itself) which are synthetic molecules. It represents a natural endogenous signalling molecule that can be exogenously supplemented to restore declining physiological levels.

MOTS-c for Research

Lyophilised MOTS-c ≥98% purity (HPLC) with full COA and mass spec verification. Synthesised with correct C-terminal free acid.

View MOTS-c →